Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Bacterial 50S ribosomal subunit – 23S rRNA cryptic site refers to a specialized binding region within the 23S ribosomal RNA (rRNA) that is not constitutively open but becomes accessible through conformational changes upon ligand binding [1, 2]. Located primarily within the peptidyl transferase center (PTC) and the nascent peptide exit tunnel (NPET), this site is essential for the catalytic formation of peptide bonds and the subsequent passage of the growing protein chain [1, 3]. It is the primary target for several important classes of antibiotics, including oxazolidinones (e.g., linezolid) and pleuromutilins (e.g., lefamulin), which exploit the flexibility of the rRNA to exert their inhibitory effects [2, 3, 5]. By occupying this cryptic pocket, these drugs interfere with the positioning of aminoacyl-tRNA or physically obstruct the exit tunnel, effectively halting bacterial protein synthesis [1, 2]. While highly selective for bacterial ribosomes, the structural similarity between the 23S rRNA and human mitochondrial rRNA can lead to off-target effects and clinical safety concerns such as myelosuppression [1, 4]. Understanding the dynamics of this cryptic site is crucial for overcoming antibiotic resistance, which often arises from mutations in the rRNA or enzymatic modifications that prevent drug access to the pocket [4, 5].
Inhibition of bacterial protein synthesis by binding to the 23S rRNA at the peptidyl transferase center (PTC) or the nascent peptide exit tunnel (NPET), which prevents the proper positioning of tRNA or blocks the progression of the growing peptide chain [1, 2, 3].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial 23S ribosomal RNA (23S rRNA) cryptic site (23S rRNA).